Mesoblast Limited
MESO
NASDAQ Global Select16.42
USD
-0.21
- -
Total Valuation
Mesoblast Limited carries a market capitalization of 2.13B, placing it among publicly traded companies globally.
| Market Cap | 2.13B |
| Enterprise Value | N/A |
Financial Position
Mesoblast Limited maintains a current ratio of 3.57, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.57 |
| Quick Ratio | 3.07 |
| Debt / Equity | 44.97 |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Stock Price Statistics
Mesoblast Limited's stock has gained approximately 8.88594% over the past 52 weeks. The 50-day moving average sits at 14.87, while the 200-day moving average is 16.22.
| Beta (5Y) | N/A |
| 52-Week Price Change | 8.88594% |
| 50-Day Moving Average | 14.87 |
| 200-Day Moving Average | 16.22 |
| Average Volume (20 Days) | N/A |
Cash Flow
| Operating Cash Flow | N/A |
| Capital Expenditures | -1.33M |
| Free Cash Flow | -1.33M |
| FCF Per Share | N/A |
Stock Splits
Mesoblast Limited's most recent stock split took place on January 10, 2024 with a 2:1 split ratio.
| Last Split Date | 1/10/2024 |
| Split Ratio | 2:1 |
Scores
Mesoblast Limited posts an Altman Z-Score of -12.55, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.55 |